Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 safety study of 20-valent pneumococcal conjugate vaccine in healthy infants
2019-003307-35Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Prevnar 20 in pneumococcal disease (2 arms), sponsored by Pfizer. Primary endpoint: Prompted local reactions. Started Apr 2020; status: completed.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2019-003307-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003307-35.